STAT editors and reporters review the widespread impact of grant cuts, layoffs and policy changes — and also discuss recent ...

Investors often view Pharmaceutical stocks as safe havens during periods of market turbulence. Indeed, shares of the three ...

Eli Lilly (LLY) is among the list of large-cap pharmaceutical companies that are awaiting the Trump administration's word on ...

US drug prices are up to five times higher than in other developed nations. Trump's order requires US drug prices to align ...

The package revives President Donald Trump’s much-maligned Most Favored Nation rule but goes further into the private markets ...

Analysts are still crunching the numbers on the impact of President Donald Trump's executive order from Monday on drug pricing. HSBC analyst Rajesh Kumar says a 20% price cut in government channels ...

Trump’s drug pricing order sparks global pharma sell-off as industry warns of stifled innovation and revenue loss in key US ...

Business leaders from major Hoosier companies say they are trying to navigate the uncertain trade environment created by ...

President Trump recently warned big drugmakers that ... the president warned that a "tariff wall" is coming. Although AbbVie, Eli Lilly, and Johnson & Johnson manufacture many of their products ...

Johnson & Johnson factored roughly $400 million into its 2025 guidance to account for the impact ... the Trump administration could unleash an even bigger threat than tariffs to AbbVie, Lilly ...